Insight

Emanuele Crupi: Antiangiogenic Therapy Combined with Immune Checkpoint Blockade in Urothelial Cancer

Emanuele Crupi/LinkedIn

Dec 23, 2024, 13:21

Emanuele Crupi: Antiangiogenic Therapy Combined with Immune Checkpoint Blockade in Urothelial Cancer

Emanuele Crupi, Fellow in Medical Oncology at San Raffaele University-Hospital, shared a post on LinkedIn about a recent paper by him and colleagues published in Bladder Cancer:

“Out now in Bladder Cancer.

Antiangiogenic Therapy Combined with Immune Checkpoint Blockade in Urothelial Cancer: Systematic Review and Meta-Analysis.

Spoiler candy:

Objective Response Rate

ICI-naïve (ICI-N): 34%
ICI-exposed (ICI-E): 16%

Looking forward to feedback and discussions from the community!”

“Antiangiogenic therapy combined with immune checkpoint blockade in urothelial cancer: Systematic review and meta-analysis”

Authors: Mohammad Moussa, Iuliia Kovalenko, Emanuele Crupi, Ekaterina Proskuriakova, Yimin Geng, Giuseppe Fallara, Raed Benkhadra, Daniele Raggi, Matthew Campbell, Pavlos Msaouel, Omar Alhalabi.

Emanuele Crupi: Antiangiogenic Therapy Combined with Immune Checkpoint Blockade in Urothelial Cancer

More posts featuring Emanuele Crupi.

antiangiogenic therapy bladder cancer cancer Daniele Raggi Ekaterina Proskuriakova Emanuele Crupi Giuseppe Fallara Iuliia Kovalenko Matthew Campbell Mohammad Moussa Omar Alhalabi OncoDaily Oncology Pavlos Msaouel Raed Benkhadra urothelial cancer Yimin Geng

New Paper Alert! HR+ Breast Cancer: Efficacy of Subsequent Treatments After CDK4/6 Inhibitor Progression

Carlos Rodriguez-Galindo: The Man Who Will Cure the World

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Tedros Adhanom Ghebreyesus: The WHO Academy has opened its door to the world

Special Coverage